Stocktwits on MSN
Travere Therapeutics, Ligand in focus as FDA set to rule on Filspari next week – first FSGS drug at stake
The FDA had extended the review of its supplemental New Drug Application for Filspari in January 2026. ・Citi kept a $48 price target for Travere, adding that it expects the FDA to approve the drug.
Learn more about whether Relay Therapeutics, Inc. or Travere Therapeutics, Inc. is a better investment based on AAII's A+ ...
Morgans healthcare analyst Iain Wilkie highlights seven ASX companies with upcoming catalysts in 2026. ... Read More The post ...
Stocktwits on MSN
OGN stock surges 20% pre-market, on track to break 200-DMA – why this buyout report has caught investor attention
Sun Pharma reportedly faces competition from two global conglomerates for Organon. ・The Indian firm reportedly made a non-binding offer for Organon in January. ・Organon reported a debt of $8.64 ...
Idiopathic Membranous Nephropathy Market Is Predicted To Reach USD 1 Billion By 2036 Due To Rising Therapeutic Options ...
Detailed price information for Kodiak Sciences Inc (KOD-Q) from The Globe and Mail including charting and trades.
View Butterfly Network, Inc. Class A BFLY stock quote prices, financial information, real-time forecasts, and company news from CNN.
View Integra LifeSciences Holdings Corporation IART stock quote prices, financial information, real-time forecasts, and company news from CNN.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results